{"id":"W2047634988","doi":"10.1111/j.1365-2141.2009.07836.x","title":"Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non‐Hodgkin lymphoma","year":2009,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Center for Research Resources; National Cancer Institute; Case Comprehensive Cancer Center, Case Western Reserve University","keywords":"Bortezomib; Mantle cell lymphoma; Fludarabine; Medicine; Rituximab; Internal medicine; Chronic lymphocytic leukemia; Follicular lymphoma; Lymphoma; Regimen; Oncology; Aggressive lymphoma; Gastroenterology; Multiple myeloma; Chemotherapy; Leukemia; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006949386,0.0001467317,0.001042965,0.0002086023,0.00006749342,0.00002912736,0.00009237495,0.0002058445,0.00001921175],"category_scores_gemma":[0.0004365077,0.0001467461,0.0001006862,0.00008240281,0.0002940739,0.0001234696,0.00004402094,0.0002200008,7.124447e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003683993,"about_ca_system_score_gemma":0.001417233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006632738,"about_ca_topic_score_gemma":0.00001200768,"domain_scores_codex":[0.9982802,0.00009172938,0.0007956633,0.0002337395,0.0002828783,0.0003157715],"domain_scores_gemma":[0.998621,0.0003109894,0.000412443,0.0001491009,0.0002443242,0.0002621319],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1963772,0.01386303,0.0001733483,0.002709516,0.0005109161,0.06320931,0.001106762,9.231519e-7,0.02205772,0.0003484385,0.02043189,0.6792109],"study_design_scores_gemma":[0.7686094,0.01117165,0.00078535,0.0005162828,0.000241507,0.2074125,0.0001679168,0.0005731584,0.007801273,0.0005532177,0.002015085,0.0001526312],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876523,0.01059386,0.0002159538,0.0004533424,0.0001453217,0.0006265874,0.0000186848,0.000006123426,0.0002878052],"genre_scores_gemma":[0.9936838,0.004205314,0.00165091,0.0001661661,0.000153172,0.000006580176,0.000005690462,0.00001922049,0.0001091955],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6790583,"threshold_uncertainty_score":0.5984132,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01446230266339019,"score_gpt":0.315413557958335,"score_spread":0.3009512552949448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}